Johnson & Johnson Reports 2014 Second-Quarter Results:

Sales of $19.5 Billion increased 9.1% Versus 2013 Second Quarter;

Second-Quarter EPS was $1.51

Excluding Special Items, 2014 Second-Quarter EPS of $1.66 increased 12.2%*

Jul 15, 2014, 07:45 ET from Johnson & Johnson

NEW BRUNSWICK, N.J., July 15, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013.  Operational results increased 9.4% and the negative impact of currency was 0.3%.  Domestic sales increased 14.9%.  International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%.

Net earnings and diluted earnings per share for the second quarter of 2014 were $4.3 billion and $1.51, respectively.  The second-quarter results included a charge for after-tax special items of approximately $0.4 billion, primarily related to an increase in the litigation accrual as well as integration and transaction costs related to the acquisition of Synthes, Inc.  Second quarter 2013 net earnings included a charge for after-tax special items of approximately $0.5 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $4.8 billion and diluted earnings per share were $1.66, representing increases of 11.3% and 12.2%, respectively, as compared to the same period in 2013.*  

"Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities," said Alex Gorsky, Chairman and Chief Executive Officer.  "Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market."

The Company increased its earnings guidance for full-year 2014 to $5.85 - $5.92 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 2.4% versus the prior year consisting of an operational increase of 3.6% and a negative impact from currency of 1.2%.   

Domestic sales decreased 0.5% primarily reflecting the divestiture of the sanitary protection business. International sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.

Positive contributors to operational results were sales of TYLENOL® and MOTRIN® analgesics; over-the-counter upper respiratory medicines as well as anti-smoking aids; NEUTROGENA® and AVEENO® skin care products; baby care products; and international sales of LISTERINE® mouthwash and feminine protection products.

Worldwide Pharmaceutical sales of $8.5 billion for the second quarter represented an increase of 21.1% versus the prior year on a total and operational basis.  Domestic sales increased 36.6%.  International sales increased 6.8% which reflected an operational increase of 6.9% and a negative currency impact of 0.1%. 

The strong sales results were primarily driven by new products including OLYSIO®/SOVRIAD® (simeprevir), for combination treatment of chronic hepatitis C in adult patients; XARELTO® (rivaroxaban), an oral anticoagulant; ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA® (canagliflozin), for the treatment of adults with type 2 diabetes; and IMBRUVICA® (ibrutinib), a kinase inhibitor for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in patients who have had at least one prior therapy.

Additional contributors to operational sales growth were STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; REMICADE® (infliximab) and SIMPONI®/SIMPONI® ARIA™ (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases;  INVEGA®  SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; and PREZISTA® (darunavir), a treatment for HIV.

Sales results were negatively impacted by loss of exclusivity for ACIPHEX® (rabeprazole), a proton pump inhibitor for gastrointestinal disorders, and CONCERTA® (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.

During the quarter, the U.S. Food and Drug Administration (FDA) and the European Commission (EC) granted approval of SYLVANT® (siltuximab) for the treatment of patients with multicentric Castleman's disease who are human immunodeficiency virus negative and human herpesvirus-8 negative. In addition, the EC granted approval for VOKANAMET®, a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet for the treatment of adults with type 2 diabetes; OLYSIO® (simeprevir) for the treatment of adult patients with genotype 1 or 4 chronic hepatitis C; and for INVEGA® (paliperidone ER) to extend its adult indication of schizophrenia to include adolescents aged 15 years and older.

In addition, a supplemental New Drug Application (sNDA) was submitted to the FDA seeking approval for simeprevir in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.  Additional sNDA's were also submitted to the FDA for once-monthly atypical long-acting antipsychotic INVEGA® SUSTENNA® (paliperidone palmitate) for approval to treat schizoaffective disorder as either monotherapy or adjunctive therapy.

A Marketing Authorization Application was submitted to the European Medicines Agency to expand the label for VELCADE® (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma.

Worldwide Medical Devices and Diagnostics sales of $7.2 billion for the second quarter represented an increase of 0.7% versus the prior year consisting of an operational increase of 0.9% and a negative currency impact of 0.2%.  Domestic sales decreased 1.4%.  International sales increased 2.3%, which reflected an operational increase of 2.6% and a negative currency impact of 0.3%.

Primary contributors to operational growth were hip and trauma products in the Orthopaedics business, Biosense Webster's electrophysiology products in the Cardiovascular Care business, and sales of energy products in the Specialty Surgery business.

Sales results in the U.S. Diabetes Care business were negatively impacted by price declines associated with the implementation of Medicare competitive bidding in mail order and retail effective July 1, 2013.

During the quarter, the SABER™ PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease received FDA and EC approval.

Subsequent to the quarter, on June 30, the Company completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; the impact of patent expirations; challenges to patents; significant adverse litigation or government action, including related to product liability claims; impact of business combinations and divestitures; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays, internally or within the supply chain; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date on which it is made. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

Percent Change

Percent Change

2014

2013

Total

Operations

Currency

2014

2013

Total

Operations

Currency

Sales to customers by

segment of business

Consumer

    U.S.

$   1,320

1,326

(0.5)

%

(0.5)

-

$   2,629

2,674

(1.7)

%

(1.7)

-

    International

2,424

2,332

3.9

5.8

(1.9)

4,672

4,659

0.3

3.3

(3.0)

3,744

3,658

2.4

3.6

(1.2)

7,301

7,333

(0.4)

1.5

(1.9)

Pharmaceutical

    U.S.

4,613

3,377

36.6

36.6

-

8,353

6,848

22.0

22.0

-

    International

3,896

3,648

6.8

6.9

(0.1)

7,654

6,945

10.2

11.6

(1.4)

8,509

7,025

21.1

21.1

0.0

16,007

13,793

16.1

16.8

(0.7)

Med Devices & Diagnostics

    U.S.

3,199

3,243

(1.4)

(1.4)

-

6,354

6,449

(1.5)

(1.5)

-

    International

4,043

3,951

2.3

2.6

(0.3)

7,948

7,807

1.8

3.6

(1.8)

7,242

7,194

0.7

0.9

(0.2)

14,302

14,256

0.3

1.3

(1.0)

U.S.

9,132

7,946

14.9

14.9

-

17,336

15,971

8.5

8.5

-

International

10,363

9,931

4.4

5.0

(0.6)

20,274

19,411

4.4

6.4

(2.0)

Worldwide

$ 19,495

17,877

9.1

%

9.4

(0.3)

$ 37,610

35,382

6.3

%

7.4

(1.1)

 

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

Percent Change

Percent Change

2014

2013

Total

Operations

Currency

2014

2013

Total

Operations

Currency

Sales to customers by

geographic area

U.S.

$   9,132

7,946

14.9

%

14.9

-

$ 17,336

15,971

8.5

%

8.5

-

Europe

5,056

4,672

8.2

4.1

4.1

9,941

9,153

8.6

5.3

3.3

Western Hemisphere excluding U.S.

1,863

1,905

(2.2)

6.5

(8.7)

3,558

3,688

(3.5)

6.8

(10.3)

Asia-Pacific, Africa

3,444

3,354

2.7

5.3

(2.6)

6,775

6,570

3.1

7.7

(4.6)

International

10,363

9,931

4.4

5.0

(0.6)

20,274

19,411

4.4

6.4

(2.0)

Worldwide

$ 19,495

17,877

9.1

%

9.4

(0.3)

$ 37,610

35,382

6.3

%

7.4

(1.1)

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings 

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

2014

2013

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$ 19,495

100.0

$ 17,877

100.0

9.1

Cost of products sold

6,039

31.0

5,489

30.7

10.0

Selling, marketing and administrative expenses

5,481

28.1

5,376

30.1

2.0

Research and development expense

2,005

10.3

1,946

10.9

3.0

In-process research and development

4

0.0

-

-

Interest (income) expense, net

114

0.6

101

0.6

Other (income) expense, net

226

1.1

172

0.9

Earnings before provision for taxes on income

5,626

28.9

4,793

26.8

17.4

Provision for taxes on income

1,300

6.7

960

5.4

35.4

Net earnings

$   4,326

22.2

$   3,833

21.4

12.9

Net earnings per share (Diluted)

$     1.51

$     1.33

13.5

Average shares outstanding (Diluted)

2,874.2

2,893.0

Effective tax rate

23.1

%

20.0

%

Adjusted earnings before provision for taxes and net earnings (1)

Earnings before provision for taxes on income

$   6,050

31.0

$   5,359

30.0

12.9

Net earnings

$   4,775

24.5

$   4,289

24.0

11.3

Net earnings per share (Diluted)

$     1.66

$     1.48

12.2

Effective tax rate

21.1

%

20.0

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings 

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

2014

2013

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$ 37,610

100.0

$ 35,382

100.0

6.3

Cost of products sold

11,494

30.6

11,043

31.2

4.1

Selling, marketing and administrative expenses

10,664

28.3

10,599

30.0

0.6

Research and development expense

3,836

10.2

3,730

10.5

2.8

In-process research and development

22

0.1

64

0.2

Interest (income) expense, net

232

0.6

205

0.6

Other (income) expense, net

312

0.8

687

1.9

Earnings before provision for taxes on income

11,050

29.4

9,054

25.6

22.0

Provision for taxes on income

1,997

5.3

1,724

4.9

15.8

Net earnings

$   9,053

24.1

$   7,330

20.7

23.5

Net earnings per share (Diluted)

$     3.15

$     2.55

23.5

Average shares outstanding (Diluted)

2,875.5

2,878.8

Effective tax rate

18.1

%

19.0

%

Adjusted earnings before provision for taxes and net earnings (1)

Earnings before provision for taxes on income

$ 11,610

30.9

$ 10,429

29.5

11.3

Net earnings

$   9,201

24.5

$   8,396

23.7

9.6

Net earnings per share (Diluted)

$     3.20

$     2.92

9.6

Effective tax rate

20.7

%

19.5

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

 

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

Second Quarter

% Incr. /

Six Months YTD

% Incr. /

(Dollars in Millions Except Per Share Data)

2014

2013

(Decr.)

2014

2013

(Decr.)

Earnings before provision for taxes on income - as reported

$ 5,626

4,793

17.4

%

$ 11,050

9,054

22.0

%

Litigation expenses

276

375

276

904

Synthes integration/transaction costs 

144

122

262

380

In-process research and development

4

-

22

64

DePuy ASRHip program

-

69

-

82

Other

-

-

-

(55)

Earnings before provision for taxes on income - as adjusted

$ 6,050

5,359

12.9

%

$ 11,610

10,429

11.3

%

Net Earnings - as reported

$ 4,326

3,833

12.9

%

$   9,053

7,330

23.5

%

Litigation expenses

342

(1)

308

342

699

Synthes integration/transaction costs 

104

87

188

270

In-process research and development

3

-

16

42

DePuy ASRHip program

-

61

-

91

Tax benefit associated with Conor Medsystems

-

-

(398)

-

Other

-

-

-

(36)

Net Earnings - as adjusted 

$ 4,775

4,289

11.3

%

$   9,201

8,396

9.6

%

Diluted Net Earnings per share - as reported

$   1.51

1.33

13.5

%

$     3.15

2.55

23.5

%

Litigation expenses

0.12

0.10

0.12

0.24

Synthes integration/transaction costs

0.03

0.03

0.06

0.09

In-process research and development

-

-

0.01

0.02

DePuy ASRHip program

-

0.02

-

0.03

Tax benefit associated with Conor Medsystems

-

-

(0.14)

-

Other

-

-

-

(0.01)

Diluted Net Earnings per share - as adjusted 

$   1.66

1.48

12.2

%

$     3.20

2.92

9.6

%

(1) Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2014

2013

Reported

Operational (1)

Currency

2014

2013

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2)

BABY CARE

US

$    107

106

0.9%

0.9%

-

$      209

209

0.0%

0.0%

-

Intl

500

480

4.2%

8.6%

-4.4%

943

941

0.2%

5.5%

-5.3%

WW

607

586

3.6%

7.2%

-3.6%

1,152

1,150

0.2%

4.6%

-4.4%

ORAL CARE

US

142

149

-4.7%

-4.7%

-

302

307

-1.6%

-1.6%

-

Intl

271

257

5.4%

7.3%

-1.9%

522

502

4.0%

7.2%

-3.2%

WW

413

406

1.7%

2.9%

-1.2%

824

809

1.9%

3.9%

-2.0%

OTC

US

316

290

9.0%

9.0%

-

682

644

5.9%

5.9%

-

Intl

687

641

7.2%

7.4%

-0.2%

1,332

1,330

0.2%

1.7%

-1.5%

WW

1,003

931

7.7%

7.8%

-0.1%

2,014

1,974

2.0%

3.0%

-1.0%

SKIN CARE

US

506

463

9.3%

9.3%

-

963

916

5.1%

5.1%

-

Intl

462

445

3.8%

4.2%

-0.4%

919

894

2.8%

4.4%

-1.6%

WW

968

908

6.6%

6.8%

-0.2%

1,882

1,810

4.0%

4.8%

-0.8%

WOMEN'S HEALTH

US

11

84

-86.9%

-86.9%

-

35

165

-78.8%

-78.8%

-

Intl

331

327

1.2%

5.4%

-4.2%

634

647

-2.0%

3.3%

-5.3%

WW

342

411

-16.8%

-13.5%

-3.3%

669

812

-17.6%

-13.4%

-4.2%

WOUND CARE/OTHER

US

238

234

1.7%

1.7%

-

438

433

1.2%

1.2%

-

Intl

173

182

-4.9%

-4.4%

-0.5%

322

345

-6.7%

-5.4%

-1.3%

WW

411

416

-1.2%

-1.0%

-0.2%

760

778

-2.3%

-1.7%

-0.6%

TOTAL CONSUMER

US

1,320

1,326

-0.5%

-0.5%

-

2,629

2,674

-1.7%

-1.7%

-

Intl

2,424

2,332

3.9%

5.8%

-1.9%

4,672

4,659

0.3%

3.3%

-3.0%

WW

$ 3,744

3,658

2.4%

3.6%

-1.2%

$   7,301

7,333

-0.4%

1.5%

-1.9%

See footnotes at end of schedule

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2014

2013

Reported

Operational (1)

Currency

2014

2013

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (3)

IMMUNOLOGY

US

$ 1,853

1,578

17.4%

17.4%

-

$   3,400

3,217

5.7%

5.7%

-

Intl

778

663

17.3%

19.1%

-1.8%

1,574

1,228

28.2%

31.8%

-3.6%

WW

2,631

2,241

17.4%

17.9%

-0.5%

4,974

4,445

11.9%

12.9%

-1.0%

REMICADE

US 

1,021

926

10.3%

10.3%

-

2,018

1,896

6.4%

6.4%

-

US Exports (4)

357

332

7.5%

7.5%

-

524

681

-23.1%

-23.1%

-

Intl

426

414

2.9%

6.3%

-3.4%

872

695

25.5%

31.0%

-5.5%

WW

1,804

1,672

7.9%

8.7%

-0.8%

3,414

3,272

4.3%

5.5%

-1.2%

SIMPONI/SIMPONI ARIA

US

132

87

51.7%

51.7%

-

236

181

30.4%

30.4%

-

Intl

150

88

70.5%

71.3%

-0.8%

305

231

32.0%

34.7%

-2.7%

WW

282

175

61.1%

61.5%

-0.4%

541

412

31.3%

32.8%

-1.5%

STELARA

US

343

233

47.2%

47.2%

-

622

459

35.5%

35.5%

-

Intl

185

138

34.1%

31.4%

2.7%

362

258

40.3%

39.2%

1.1%

WW

528

371

42.3%

41.3%

1.0%

984

717

37.2%

36.8%

0.4%

OTHER IMMUNOLOGY

US

-

-

-

-

-

-

-

-

-

-

Intl

17

23

-26.1%

-22.7%

-3.4%

35

44

-20.5%

-14.6%

-5.9%

WW

17

23

-26.1%

-22.7%

-3.4%

35

44

-20.5%

-14.6%

-5.9%

INFECTIOUS DISEASES

US

1,020

259

*

*

-

1,581

497

*

*

-

Intl

742

711

4.4%

3.5%

0.9%

1,381

1,288

7.2%

6.6%

0.6%

WW

1,762

970

81.6%

80.9%

0.7%

2,962

1,785

65.9%

65.5%

0.4%

EDURANT

US

6

3

100.0%

100.0%

-

11

6

83.3%

83.3%

-

Intl

86

53

62.3%

57.7%

4.6%

162

93

74.2%

70.3%

3.9%

WW

92

56

64.3%

60.0%

4.3%

173

99

74.7%

71.0%

3.7%

INCIVO

US

-

-

-

-

-

-

-

-

-

-

Intl

97

172

-43.6%

-42.5%

-1.1%

183

334

-45.2%

-44.8%

-0.4%

WW

97

172

-43.6%

-42.5%

-1.1%

183

334

-45.2%

-44.8%

-0.4%

OLYSIO/SOVRIAD

US

725

-

*

*

-

1,016

-

*

*

-

Intl

106

-

*

*

0.0%

169

-

*

*

0.0%

WW

831

-

*

*

0.0%

1,185

-

*

*

0.0%

PREZISTA

US

239

196

21.9%

21.9%

-

453

363

24.8%

24.8%

-

Intl

253

239

5.9%

4.7%

1.2%

484

439

10.3%

9.6%

0.7%

WW

492

435

13.1%

12.4%

0.7%

937

802

16.8%

16.4%

0.4%

OTHER INFECTIOUS DISEASES

US

50

60

-16.7%

-16.7%

-

101

128

-21.1%

-21.1%

-

Intl

200

247

-19.0%

-19.6%

0.6%

383

422

-9.2%

-9.0%

-0.2%

WW

250

307

-18.6%

-19.0%

0.4%

484

550

-12.0%

-11.9%

-0.1%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2014

2013

Reported

Operational (1)

Currency

2014

2013

Reported

Operational (1)

Currency

NEUROSCIENCE

US

600

626

-4.2%

-4.2%

-

1,201

1,372

-12.5%

-12.5%

-

Intl

1,027

1,054

-2.6%

-2.4%

-0.2%

2,064

2,052

0.6%

2.5%

-1.9%

WW

1,627

1,680

-3.2%

-3.1%

-0.1%

3,265

3,424

-4.6%

-3.5%

-1.1%

CONCERTA/METHYLPHENIDATE

US

28

85

-67.1%

-67.1%

-

63

224

-71.9%

-71.9%

-

Intl

117

130

-10.0%

-8.3%

-1.7%

232

247

-6.1%

-3.0%

-3.1%

WW

145

215

-32.6%

-31.6%

-1.0%

295

471

-37.4%

-35.8%

-1.6%

INVEGA

US

89

76

17.1%

17.1%

-

175

147

19.0%

19.0%

-

Intl

69

74

-6.8%

-7.5%

0.7%

148

135

9.6%

11.3%

-1.7%

WW

158

150

5.3%

5.0%

0.3%

323

282

14.5%

15.3%

-0.8%

INVEGA SUSTENNA/ XEPLION

US

202

158

27.8%

27.8%

-

384

322

19.3%

19.3%

-

Intl

192

132

45.5%

42.3%

3.2%

383

252

52.0%

51.0%

1.0%

WW

394

290

35.9%

34.4%

1.5%

767

574

33.6%

33.2%

0.4%

RISPERDAL CONSTA

US

110

107

2.8%

2.8%

-

216

213

1.4%

1.4%

-

Intl

192

229

-16.2%

-17.7%

1.5%

396

458

-13.5%

-13.4%

-0.1%

WW

302

336

-10.1%

-11.1%

1.0%

612

671

-8.8%

-8.7%

-0.1%

OTHER NEUROSCIENCE

US

171

200

-14.5%

-14.5%

-

363

466

-22.1%

-22.1%

-

Intl

457

489

-6.5%

-4.9%

-1.6%

905

960

-5.7%

-2.4%

-3.3%

WW

628

689

-8.9%

-7.8%

-1.1%

1,268

1,426

-11.1%

-8.9%

-2.2%

ONCOLOGY

US

278

206

35.0%

35.0%

-

518

405

27.9%

27.9%

-

Intl

833

679

22.7%

21.6%

1.1%

1,615

1,274

26.8%

27.1%

-0.3%

WW

1,111

885

25.5%

24.6%

0.9%

2,133

1,679

27.0%

27.2%

-0.2%

VELCADE

US

-

-

-

-

-

-

-

-

-

-

Intl

403

379

6.3%

6.2%

0.1%

811

732

10.8%

12.2%

-1.4%

WW

403

379

6.3%

6.2%

0.1%

811

732

10.8%

12.2%

-1.4%

ZYTIGA

US

235

174

35.1%

35.1%

-

464

335

38.5%

38.5%

-

Intl

327

221

48.0%

45.1%

2.9%

610

404

51.0%

49.4%

1.6%

WW

562

395

42.3%

40.7%

1.6%

1,074

739

45.3%

44.4%

0.9%

OTHER ONCOLOGY

US

43

32

34.4%

34.4%

-

54

70

-22.9%

-22.9%

-

Intl

103

79

30.4%

29.2%

1.2%

194

138

40.6%

40.7%

-0.1%

WW

146

111

31.5%

30.6%

0.9%

248

208

19.2%

19.2%

0.0%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2014

2013

Reported

Operational (1)

Currency

2014

2013

Reported

Operational (1)

Currency

TOTAL OTHER

US

862

708

21.8%

21.8%

-

1,653

1,357

21.8%

21.8%

-

Intl

516

541

-4.6%

-4.7%

0.1%

1,020

1,103

-7.5%

-6.7%

-0.8%

WW

1,378

1,249

10.3%

10.3%

0.0%

2,673

2,460

8.7%

9.0%

-0.3%

PROCRIT/EPREX

US

178

190

-6.3%

-6.3%

-

354

423

-16.3%

-16.3%

-

Intl

141

145

-2.8%

-3.4%

0.6%

275

290

-5.2%

-5.0%

-0.2%

WW

319

335

-4.8%

-5.1%

0.3%

629

713

-11.8%

-11.7%

-0.1%

XARELTO

US

361

189

91.0%

91.0%

-

680

347

96.0%

96.0%

-

Intl

-

-

-

-

-

-

-

-

-

-

WW

361

189

91.0%

91.0%

-

680

347

96.0%

96.0%

-

OTHER

US

323

329

-1.8%

-1.8%

-

619

587

5.5%

5.5%

-

Intl

375

396

-5.3%

-5.1%

-0.2%

745

813

-8.4%

-7.4%

-1.0%

WW

698

725

-3.7%

-3.6%

-0.1%

1,364

1,400

-2.6%

-2.0%

-0.6%

TOTAL PHARMACEUTICAL

US

4,613

3,377

36.6%

36.6%

-

8,353

6,848

22.0%

22.0%

-

Intl

3,896

3,648

6.8%

6.9%

-0.1%

7,654

6,945

10.2%

11.6%

-1.4%

WW

$ 8,509

7,025

21.1%

21.1%

0.0%

$ 16,007

13,793

16.1%

16.8%

-0.7%

See footnotes at end of schedule

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2014

2013

Reported

Operational (1)

Currency

2014

2013

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2) (3)

CARDIOVASCULAR CARE

US

$    214

204

4.9%

4.9%

-

$      419

402

4.2%

4.2%

-

Intl

353

325

8.6%

8.7%

-0.1%

689

640

7.7%

9.1%

-1.4%

WW

567

529

7.2%

7.3%

-0.1%

1,108

1,042

6.3%

7.2%

-0.9%

DIABETES CARE

US

222

259

-14.3%

-14.3%

-

414

542

-23.6%

-23.6%

-

Intl

336

330

1.8%

1.8%

0.0%

656

647

1.4%

2.4%

-1.0%

WW

558

589

-5.3%

-5.3%

0.0%

1,070

1,189

-10.0%

-9.5%

-0.5%

DIAGNOSTICS

US

232

241

-3.7%

-3.7%

-

456

489

-6.7%

-6.7%

-

Intl

229

242

-5.4%

-4.3%

-1.1%

448

471

-4.9%

-2.6%

-2.3%

WW

461

483

-4.6%

-4.1%

-0.5%

904

960

-5.8%

-4.7%

-1.1%

ORTHOPAEDICS

US 

1,294

1,274

1.6%

1.6%

-

2,586

2,535

2.0%

2.0%

-

Intl

1,175

1,111

5.8%

5.3%

0.5%

2,304

2,235

3.1%

4.1%

-1.0%

WW

2,469

2,385

3.5%

3.3%

0.2%

4,890

4,770

2.5%

3.0%

-0.5%

SPECIALTY SURGERY/OTHER (5)

US

424

426

-0.5%

-0.5%

-

841

830

1.3%

1.3%

-

Intl

481

464

3.7%

4.7%

-1.0%

938

899

4.3%

6.8%

-2.5%

WW

905

890

1.7%

2.2%

-0.5%

1,779

1,729

2.9%

4.2%

-1.3%

SURGICAL CARE 

US

551

577

-4.5%

-4.5%

-

1,090

1,108

-1.6%

-1.6%

-

Intl

1,024

1,011

1.3%

1.9%

-0.6%

1,993

1,988

0.3%

2.1%

-1.8%

WW

1,575

1,588

-0.8%

-0.4%

-0.4%

3,083

3,096

-0.4%

0.8%

-1.2%

VISION CARE

US

262

262

0.0%

0.0%

-

548

543

0.9%

0.9%

-

Intl

445

468

-4.9%

-4.0%

-0.9%

920

927

-0.8%

2.9%

-3.7%

WW

707

730

-3.2%

-2.7%

-0.5%

1,468

1,470

-0.1%

2.2%

-2.3%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US

3,199

3,243

-1.4%

-1.4%

-

6,354

6,449

-1.5%

-1.5%

-

Intl

4,043

3,951

2.3%

2.6%

-0.3%

7,948

7,807

1.8%

3.6%

-1.8%

WW

$ 7,242

7,194

0.7%

0.9%

-0.2%

$ 14,302

14,256

0.3%

1.3%

-1.0%

* Percentage greater than 100%

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Prior year amounts have been reclassified to conform to current year product disclosure

(4) Reported as U.S. sales

(5) Infection Prevention now reflected in Specialty Surgery/Other, previously reported independently

 

SOURCE Johnson & Johnson



RELATED LINKS

http://www.jnj.com